{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:09:23Z","timestamp":1793045363484,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.kint.2023.02.010","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T16:31:04Z","timestamp":1677774664000},"page":"859-871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Drug repurposing in autosomal dominant polycystic kidney disease"],"prefix":"10.1016","volume":"103","author":[{"given":"Julie Xia","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2023.02.010_bib1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks?","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.kint.2023.02.010_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.kint.2023.02.010_bib3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.010_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.981963","article-title":"Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling","volume":"9","author":"Zhou","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.kint.2023.02.010_bib5","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.02.010_bib6","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.02.010_bib7","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.02.010_bib8","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.kint.2023.02.010_bib9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.26140","article-title":"Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases","volume":"58","author":"Masyuk","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.kint.2023.02.010_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002777","article-title":"Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): a randomized, double-blind, placebo-controlled, multicenter trial","volume":"16","author":"Perico","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.kint.2023.02.010_bib11","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2023.02.010_bib12","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney\u00a0function in patients with autosomal dominant polycystic kidney\u00a0disease: the DIPAK 1 randomized clinical trial","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2023.02.010_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1681\/ASN.2013121312","article-title":"Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model","volume":"26","author":"Hopp","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.010_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.prostaglandins.2014.10.005","article-title":"Cyclooxygenase product inhibition with acetylsalicylic acid slows disease progression in the Han:SPRD-Cy rat model of polycystic kidney disease","volume":"116\u2013117","author":"Ibrahim","year":"2015","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.kint.2023.02.010_bib15","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1126\/science.1215327","article-title":"The ancient drug salicylate directly activates AMP-activated protein kinase","volume":"336","author":"Hawley","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.kint.2023.02.010_bib16","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ebiom.2019.08.041","article-title":"Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease","volume":"47","author":"Leonhard","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.kint.2023.02.010_bib17","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/jgs.14065","article-title":"Renal toxicity associated with salsalate in elderly adults with anemia","volume":"64","author":"Cohen","year":"2016","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.kint.2023.02.010_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/1573402116666200817113125","article-title":"Serum uric acid and progression of autosomal dominant polycystic kidney disease: results from the HALT PKD trials","volume":"17","author":"Brosnahan","year":"2021","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.kint.2023.02.010_bib19","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2215\/CJN.03250410","article-title":"Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease","volume":"6","author":"Torres","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.010_bib20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1471-2369-15-63","article-title":"Hyperuricemia and deterioration of renal function in autosomal dominant polycystic kidney disease","volume":"15","author":"Han","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2023.02.010_bib21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/nep.13407","article-title":"Baseline characteristics of the autosomal-dominant polycystic kidney disease sub-cohort of the KoreaN cohort study for outcomes in patients with chronic kidney disease","volume":"24","author":"Kim","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.kint.2023.02.010_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026559","article-title":"Primary prevention of cardiovascular disease events with renin-angiotensin system blockade in autosomal dominant polycystic kidney disease dialysis patients: a nationwide cohort study","volume":"100","author":"Lu","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.kint.2023.02.010_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.752174","article-title":"Drug-repositioning approaches based on medical and life science databases","volume":"12","author":"Zamami","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.kint.2023.02.010_bib24","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.drudis.2011.05.009","article-title":"Electronic health records: implications for drug discovery","volume":"16","author":"Yao","year":"2011","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.kint.2023.02.010_bib25","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.2196\/jmir.4541","article-title":"Opportunities for Web-based drug repositioning: searching for potential antihypertensive agents with hypotension adverse events","volume":"18","author":"Wang","year":"2016","journal-title":"J\u00a0Med Internet Res"},{"key":"10.1016\/j.kint.2023.02.010_bib26","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.kint.2020.10.041","article-title":"Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity","volume":"99","author":"Hamano","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.02.010_bib27","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100774R","article-title":"Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease","volume":"35","author":"Di Mise","year":"2021","journal-title":"FASEB J"},{"key":"10.1016\/j.kint.2023.02.010_bib28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2023.02.010_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw3593","article-title":"Activation of P-TEFb by cAMP-PKA signaling in autosomal dominant polycystic kidney disease","volume":"5","author":"Sun","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.kint.2023.02.010_bib30","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0272-6386(98)70072-1","article-title":"Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease","volume":"32","author":"O'Sullivan","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2023.02.010_bib31","first-page":"529","article-title":"Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis","volume":"19","author":"Xu","year":"2006","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.kint.2023.02.010_bib32","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1681\/ASN.2007070828","article-title":"Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease","volume":"19","author":"Yang","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.010_bib33","doi-asserted-by":"crossref","first-page":"17090","DOI":"10.1074\/jbc.RA119.010320","article-title":"Pharmacological reversal of renal cysts from secretion to absorption suggests a potential therapeutic strategy for managing autosomal dominant polycystic kidney disease","volume":"294","author":"Yanda","year":"2019","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2023.02.010_bib34","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202101315R","article-title":"VX-809 mitigates disease in a mouse model of autosomal dominant polycystic kidney disease bearing the R3277C human mutation","volume":"35","author":"Yanda","year":"2021","journal-title":"FASEB J"},{"key":"10.1016\/j.kint.2023.02.010_bib35","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.1074\/jbc.RA118.001846","article-title":"A\u00a0potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector","volume":"293","author":"Yanda","year":"2018","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2023.02.010_bib36","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1038\/s41467-020-18104-5","article-title":"Cyst growth in ADPKD is prevented by pharmacological and genetic inhibition of TMEM16A in\u00a0vivo","volume":"11","author":"Cabrita","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2023.02.010_bib37","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A\u00a0benefit-risk assessment of benzbromarone in the treatment of gout: was its withdrawal from the market in the best interest of patients?","volume":"31","author":"Lee","year":"2008","journal-title":"Drug Saf"},{"key":"10.1016\/j.kint.2023.02.010_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cellsig.2017.04.001","article-title":"Niclosamide: beyond an antihelminthic drug","volume":"41","author":"Chen","year":"2018","journal-title":"Cell Signal"},{"key":"10.1016\/j.kint.2023.02.010_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.128414","article-title":"Niclosamide repurposed for the treatment of inflammatory airway disease","volume":"4","author":"Cabrita","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2023.02.010_bib40","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ki.2008.246","article-title":"KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease","volume":"74","author":"Albaqumi","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.02.010_bib41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/MNH.0000000000000751","article-title":"KCa3.1 in diabetic kidney disease","volume":"31","author":"Huang","year":"2022","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kint.2023.02.010_bib42","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1111\/bjh.17345","article-title":"Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the phase III trial","volume":"192","author":"Ataga","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.kint.2023.02.010_bib43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.33594\/000000374","article-title":"Targeting Kca3.1 channels in cancer","volume":"55","author":"Todesca","year":"2021","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.kint.2023.02.010_bib44","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5527\/wjn.v6.i4.188","article-title":"Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease","volume":"6","author":"Sweeney","year":"2017","journal-title":"World J Nephrol"},{"key":"10.1016\/j.kint.2023.02.010_bib45","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41419-021-04248-9","article-title":"The tyrosine-kinase inhibitor nintedanib ameliorates autosomal-dominant polycystic kidney disease","volume":"12","author":"Jamadar","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.kint.2023.02.010_bib46","doi-asserted-by":"crossref","first-page":"C522","DOI":"10.1152\/ajpcell.00163.2010","article-title":"c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation","volume":"301","author":"Elliott","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.kint.2023.02.010_bib47","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1681\/ASN.2007060665","article-title":"Src inhibition ameliorates polycystic kidney disease","volume":"19","author":"Sweeney","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.010_bib48","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1681\/ASN.2016111232","article-title":"Bosutinib versus placebo for autosomal dominant polycystic kidney disease","volume":"28","author":"Tesar","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.010_bib49","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1074\/jbc.275.1.223","article-title":"Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I","volume":"275","author":"El-Mir","year":"2000","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2023.02.010_bib50","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2023.02.010_bib51","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1152\/ajprenal.00298.2021","article-title":"Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model","volume":"322","author":"Pastor-Soler","year":"2022","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2023.02.010_bib52","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/hmg\/ddab340","article-title":"Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice","volume":"31","author":"Chang","year":"2022","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.kint.2023.02.010_bib53","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2021.06.013","article-title":"Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)","volume":"100","author":"Perrone","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.02.010_bib54","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/j.ajkd.2021.06.026","article-title":"Metformin therapy in autosomal dominant polycystic kidney disease: a feasibility study","volume":"79","author":"Brosnahan","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"suppl 2","key":"10.1016\/j.kint.2023.02.010_bib55","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1002\/dmrr.249","article-title":"The mode of action of thiazolidinediones","volume":"18","author":"Hauner","year":"2002","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.kint.2023.02.010_bib56","doi-asserted-by":"crossref","first-page":"E175","DOI":"10.1152\/ajpendo.00453.2005","article-title":"Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues","volume":"291","author":"LeBrasseur","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.kint.2023.02.010_bib57","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/274376","article-title":"Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease","volume":"2010","author":"Blazer-Yost","year":"2010","journal-title":"PPAR Res"},{"key":"10.1016\/j.kint.2023.02.010_bib58","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/ckj\/sfaa232","article-title":"A\u00a0randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease","volume":"14","author":"Blazer-Yost","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2023.02.010_bib59","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1681\/ASN.2015030231","article-title":"2-Deoxy-d-glucose ameliorates PKD progression","volume":"27","author":"Chiaravalli","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.010_bib60","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bph.14558","article-title":"The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease","volume":"176","author":"Lian","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.kint.2023.02.010_bib61","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41420-019-0156-8","article-title":"Low-dose 2-deoxyglucose and metformin synergically inhibit proliferation of human polycystic kidney cells by modulating glucose metabolism","volume":"5","author":"Zhao","year":"2019","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.kint.2023.02.010_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114213","article-title":"Cellular toxicity of the metabolic inhibitor 2-deoxyglucose and associated resistance mechanisms","volume":"182","author":"Laussel","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.kint.2023.02.010_bib63","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.02.010_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1011669","article-title":"Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy","volume":"13","author":"Du","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.kint.2023.02.010_bib65","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2215\/CJN.09380822","article-title":"Kidney-protective effects of SGLT2 inhibitors","volume":"18","author":"Palmer","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.010_bib66","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14360","article-title":"Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume","volume":"8","author":"Masuda","year":"2020","journal-title":"Physiol Rep"},{"key":"10.1016\/j.kint.2023.02.010_bib67","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.199","article-title":"Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats","volume":"84","author":"Wang","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.02.010_bib68","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1159\/000368540","article-title":"Inhibition of sodium-glucose cotransporter 2 with dapagliflozin in Han: SPRD rats with polycystic kidney disease","volume":"40","author":"Rodriguez","year":"2015","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.kint.2023.02.010_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125603","article-title":"Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats","volume":"10","author":"Kapoor","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2023.02.010_bib70","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/ki.2010.457","article-title":"mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression","volume":"79","author":"Huber","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.02.010_bib71","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.molmed.2011.06.003","article-title":"mTOR signaling in polycystic kidney disease","volume":"17","author":"Ibraghimov-Beskrovnaya","year":"2011","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.kint.2023.02.010_bib72","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.02.010_bib73","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.02.010_bib74","doi-asserted-by":"crossref","first-page":"F395","DOI":"10.1152\/ajprenal.00057.2018","article-title":"Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease","volume":"315","author":"Kipp","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2023.02.010_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.683247","article-title":"Targeted drug delivery systems for kidney diseases","volume":"9","author":"Huang","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.kint.2023.02.010_bib76","doi-asserted-by":"crossref","first-page":"F122","DOI":"10.1152\/ajprenal.00352.2017","article-title":"PPARalpha agonist fenofibrate enhances fatty acid beta-oxidation and attenuates polycystic kidney and liver disease in mice","volume":"314","author":"Lakhia","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2023.02.010_bib77","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2146\/ajhp120131","article-title":"Fenofibrate-associated nephrotoxicity: a review of current evidence","volume":"70","author":"Attridge","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.kint.2023.02.010_bib78","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2023.02.010_bib79","doi-asserted-by":"crossref","first-page":"328","DOI":"10.31662\/jmaj.2021-0212","article-title":"Effect of pemafibrate on serum creatinine in patients with chronic kidney disease","volume":"5","author":"Imai","year":"2022","journal-title":"JMA J"},{"key":"10.1016\/j.kint.2023.02.010_bib80","doi-asserted-by":"crossref","first-page":"eaba3613","DOI":"10.1126\/scitranslmed.aba3613","article-title":"Activation of NRF2 ameliorates oxidative stress and cystogenesis in autosomal dominant polycystic kidney disease","volume":"12","author":"Lu","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.kint.2023.02.010_bib81","doi-asserted-by":"crossref","first-page":"5440","DOI":"10.1002\/ptr.7176","article-title":"Sulforaphane: a review of its therapeutic potentials, advances in its nanodelivery, recent patents, and clinical trials","volume":"35","author":"Mangla","year":"2021","journal-title":"Phytother Res"},{"key":"10.1016\/j.kint.2023.02.010_bib82","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.02.010_bib83","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2215\/CJN.02400222","article-title":"Effects of bardoxolone methyl in Alport syndrome","volume":"17","author":"Warady","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.010_bib84","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s42003-021-02730-w","article-title":"Metabolic derangement in polycystic kidney disease mouse models is ameliorated by mitochondrial-targeted antioxidants","volume":"4","author":"Daneshgar","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.kint.2023.02.010_bib85","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00337-17","article-title":"Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease","volume":"37","author":"Ishimoto","year":"2017","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.kint.2023.02.010_bib86","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0272-6386(00)70330-1","article-title":"Effect of probucol in a murine model of slowly progressive polycystic kidney disease","volume":"35","author":"Nagao","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2023.02.010_bib87","doi-asserted-by":"crossref","first-page":"21819","DOI":"10.1073\/pnas.0911987106","article-title":"Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models","volume":"106","author":"Cao","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2023.02.010_bib88","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1172\/JCI64401","article-title":"Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease","volume":"123","author":"Zhou","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2023.02.010_bib89","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ekir.2020.06.002","article-title":"Biological efficacy and safety of niacinamide in patients with ADPKD","volume":"5","author":"El Ters","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2023.02.010_bib90","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1177\/2472555217716056","article-title":"High-throughput phenotypic screening of kinase inhibitors to identify drug targets for polycystic kidney disease","volume":"22","author":"Booij","year":"2017","journal-title":"SLAS Discov"},{"key":"10.1016\/j.kint.2023.02.010_bib91","doi-asserted-by":"crossref","first-page":"12859","DOI":"10.1073\/pnas.1405362111","article-title":"Nedd9 restrains renal cystogenesis in Pkd1(-\/-) mice","volume":"111","author":"Nikonova","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2023.02.010_bib92","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1038\/s41598-020-61082-3","article-title":"A\u00a0high-throughput screening platform for polycystic kidney disease (PKD) drug repurposing utilizing murine and human ADPKD cells","volume":"10","author":"Asawa","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2023.02.010_bib93","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.stem.2022.06.005","article-title":"A\u00a0scalable organoid model of human autosomal dominant polycystic kidney disease for disease mechanism and drug discovery","volume":"29","author":"Tran","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.kint.2023.02.010_bib94","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.stem.2018.04.022","article-title":"High-throughput screening enhances kidney organoid differentiation from human pluripotent stem cells and enables automated multidimensional phenotyping","volume":"22","author":"Czerniecki","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.kint.2023.02.010_bib95","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nmat4994","article-title":"Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidney disease","volume":"16","author":"Cruz","year":"2017","journal-title":"Nat Mater"},{"key":"10.1016\/j.kint.2023.02.010_bib96","doi-asserted-by":"crossref","first-page":"8715","DOI":"10.1038\/ncomms9715","article-title":"Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids","volume":"6","author":"Freedman","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2023.02.010_bib97","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1681\/ASN.2020030378","article-title":"PKD1-dependent renal cystogenesis in human induced pluripotent stem cell-derived ureteric bud\/collecting duct organoids","volume":"31","author":"Kuraoka","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.010_bib98","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41598-019-56995-7","article-title":"A\u00a0high throughput zebrafish chemical screen reveals ALK5 and non-canonical androgen signalling as modulators of the pkd2(-\/-) phenotype","volume":"10","author":"Metzner","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2023.02.010_bib99","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A\u00a0genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.kint.2023.02.010_bib100","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1038\/s41467-022-31030-y","article-title":"Common genetic variation associated with Mendelian disease severity revealed through cryptic phenotype analysis","volume":"13","author":"Blair","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2023.02.010_bib101","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/hmg\/ddp165","article-title":"Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks","volume":"18","author":"Song","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.kint.2023.02.010_bib102","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1752-0509-5-56","article-title":"Systems biology approach to identify transcriptome reprogramming and candidate microRNA targets during the progression of polycystic kidney disease","volume":"5","author":"Pandey","year":"2011","journal-title":"BMC Syst Biol"},{"key":"10.1016\/j.kint.2023.02.010_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.11.046","article-title":"Prioritization of novel ADPKD drug candidates from disease-stage specific gene expression profiles","volume":"51","author":"Malas","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.kint.2023.02.010_bib104","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1038\/s41467-022-34255-z","article-title":"Defining cellular complexity in human autosomal dominant polycystic kidney disease by multimodal single cell analysis","volume":"13","author":"Muto","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2023.02.010_bib105","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.kint.2023.02.010_bib106","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A\u00a0next generation Connectivity Map: L1000 platform and the first 1,000,000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.kint.2023.02.010_bib107","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2215\/CJN.12191018","article-title":"Proteomic analysis of urinary microvesicles and exosomes in medullary sponge kidney disease and autosomal dominant polycystic kidney disease","volume":"14","author":"Bruschi","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.010_bib108","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1681\/ASN.2015090994","article-title":"Proteomics of urinary vesicles links plakins and complement to polycystic kidney disease","volume":"27","author":"Salih","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.010_bib109","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1681\/ASN.2008060564","article-title":"Characterization of PKD\u00a0protein-positive exosome-like vesicles","volume":"20","author":"Hogan","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.010_bib110","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/ki.2015.207","article-title":"A\u00a0polycystin-centric view of cyst formation and disease: the polycystins revisited","volume":"88","author":"Ong","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.02.010_bib111","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41588-021-00946-4","article-title":"Renal plasticity revealed through reversal of polycystic kidney disease in mice","volume":"53","author":"Dong","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2023.02.010_bib112","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1038\/s41467-019-11918-y","article-title":"Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease","volume":"10","author":"Lee","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2023.02.010_bib113","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1681\/ASN.2006080835","article-title":"Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease","volume":"17","author":"Harris","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.010_bib114","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.00550110","article-title":"Evidence of extraordinary growth in the progressive enlargement of renal cysts","volume":"5","author":"Grantham","year":"2010","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823001333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823001333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T05:34:11Z","timestamp":1715146451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253823001333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":114,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0085253823001333"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2023.02.010","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing in autosomal dominant polycystic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2023.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2023.03.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier, Inc., on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}